ABOUT THIS EPISODE

English
Australia

TRANSCRIPT 🔗

SEARCH PAST EPISODES

Search past episodes of Homodeus Research.

OTHER EPISODES IN THIS PODCAST

Can Aureka Limited (ASX) transform from a Victorian gold explorer into a producer while continuing to advance its larger growth projects? In this episode of the Homodeus Research Podcast, Managing Director James Gurry discusses Aureka’s proposed acquisition of High Grade Holdings and Core Prospecti…
Could RareX (ASX) be entering a new phase as exploration at Khaleesi shows signs of a potential copper porphyry system while the company advances its broader rare earths and critical minerals strategy? In this episode of the Homodeus Research Podcast, RareX Managing Director James Durrant discusses…
Can Dimerix build a global kidney disease business around two clinical-stage drug candidates? Dimerix (ASX: DXB) Managing Director and CEO Nina Webster joins Homodeus Research to discuss the company’s kidney disease pipeline, led by DMX200 and DMX652. DMX200 is being evaluated as a potential treatm…
Neurizon Therapeutics (ASX) is approaching a critical period in the development of NUZ-001 for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease (MND). In this episode of the Homodeus Research Podcast, Interim Executive Chair Sergio Duchini and CFO Dan O'Connell disc…
Disclaimer: The podcast and artwork embedded on this page are from Homodeus Research, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.